Pavia

• A Multicenter, Randomized, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenan … Ended
  2024-513569-38-00 10 2021-07-09 Crohn's Disease
• A Study of the Efficacy and Safety of MK-5475 in Participants with Pulmonary Arterial Hypertension Ended
  2022-500877-15-00 10 2021-06-25 Pulmonary arterial hypertension (PAH) in one of the following groups:
• A dual-cohort, open-label, phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cel … Ended
  2023-509155-14-00 4 2021-06-10 Peripheral T-cell Lymphoma
• Non-inferiority study of GSK3511294 (depemokimab) compared with mepolizumab or benralizumab in participants with severe asthma with an eosin … Ended
  2023-510230-84-00 5 2021-05-28 Severe asthma with an eosinophilic phenotype
• Phase 2 study of Pembrolizumab given every 6 weeks to participants diagnosed with Relapsed or Refractory Classical Hodgkin’s Lymphoma (rrcHL … Ended
  2024-510979-38-00 4 2021-05-27 Relapsed or refractory Classical Hodgkins Lymphoma and relapsed or ref
• The aim of the study is to evaluate the efficacy of Ponatinib, either alone or in combination with chemotherapy, in inducing remission in pa … Ended
  2024-516868-28-00 4 2021-05-04 Ph+ Acute Lymphoblastic Leukemia
• Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis Ended
  2024-513075-40-00 4 2021-03-01 Relapsed or refractory AL amyloidosis
• A study to evaluate the effects of ALIS based treatment in patients newly diagnosed with nontuberculous mycobacterial lung infection caused … Ended
  2023-505273-33-00 5 2021-02-15 "Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM
• A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants (from 1 mo … Ended
  2023-507850-33-00 5 2021-02-05 Hematopoietic stem cell transplant-associated thrombotic microangiopat
• A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS2) Ended
  2023-506724-85-00 5 2020-11-19 Migraine
• A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS1) Ended
  2023-506253-38-00 5 2020-11-09 Migraine
• A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents Ended
  2024-512837-34-00 5 2020-10-14 Episodic and Chronic Migraine
• A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cel … Ended
  2022-502480-38-00 5 2020-09-09 Non−small cell lung cancer (NSCLC)
• A Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherap … Ended
  2022-501531-16-00 5 2020-01-24 esophageal carcinoma
• A study to Evaluate Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy Ended
  2023-508364-29-00 5 2019-11-22 Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
• A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants with Open-Angle Glaucoma or Ocular Hypertension Ended
  2022-502380-37-00 5 2019-08-02 Open-Angle Glaucoma
• Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine Ended
  2023-504928-26-00 5 2019-07-19 Chronic Migraine
• Pembrolizumab with Lenvatinib versus Docetaxel for Metastatic NSCLC after Platinum Doublet Chemotherapy and Immunotherapy Ended
  2022-501439-18-00 5 2019-06-26 NSCLC with squamous or nonsquamous histology
• A study evaluating the efficacy and safety of ralinepag in treatment of patients with pulmonary arterial hypertension. Ended
  2023-509304-16-00 5 2019-05-16 Pulmonary arterial hypertension (PAH)
• HELIOS-A: A Phase 3 Global Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients with Hereditary Transthyretin Amyloidosis Ended
  2023-508365-33-00 5 2019-04-09 Hereditary Transthyretin Amyloidosis
• A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients with Relapsed or Refractory AML or CMML Ended
  2023-508655-39-00 7 2019-02-13 Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia(CMML)
• Phase 1/2 Dose Finding, Safety and Efficacy Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD) Ended
  2023-507330-24-00 9 2019-02-07 Chronic Graft Versus Host Disease (cGVHD)
• Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn's Disease Ended
  2024-511553-22-00 5 2018-10-05 Moderately to Severely Active Crohn's Disease
• Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Active Crohn's Disease Ended
  2023-510426-33-00 5 2018-09-27 Moderately to Severely Active Crohn's Disease

Showing 529–552 of 566 trials